The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Status:
Completed
Trial end date:
2022-04-06
Target enrollment:
Participant gender:
Summary
This is a non-randomized, prospective, single-group longitudinal study. The purpose of this
study is to improve the decision making process used by physicians and patients when they are
considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Barbara Ann Karmanos Cancer Institute Dana-Farber Cancer Institute Duke Cancer Institute Emory University Fred Hutchinson Cancer Center H. Lee Moffitt Cancer Center and Research Institute Memorial Sloan Kettering Cancer Center University of California, San Francisco University of Chicago University of Utah Weill Medical College of Cornell University